ReviewFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
The Critical Role of GALNTs-Regulated O-GalNAc Glycosylation in Cancer Malignancy.
Review in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Aberrant mucin-type O-glycosylation, mediated by the Polypeptide N-acetylgalactosaminyltransferase (GALNT) family of enzymes, is a defining feature of many cancers and has also been strongly linked to non-neoplastic conditions, including developmental disorders and metabolic abnormalities. Mucin-type O-GalNAc glycosylation, a prevalent and highly specific form of post-translational modification, is centrally involved in key processes underlying cancer progression, such as cell signaling, invasion, angiogenesis, and metastasis. It is intricately linked to a diverse array of human diseases, with a particular association with cancer. Ongoing research endeavors to elucidate the functional mechanisms by which GALNT enzymes regulate O-GalNAc glycosylation, thereby enhancing our understanding of their pivotal roles in cancer biology. Although significant advances have been made in understanding their contributions to cancer initiation and progression, a comprehensive characterization of both the GALNT family and O-GalNAc glycosylation in oncology remains lacking. This review aims to summarize the structure of the GALNT family and its regulatory roles in the initiation and elongation of O-GalNAc glycans, providing an in-depth exploration of the functions of GALNT-mediated O-GalNAc glycosylation in cancer. Ultimately, these insights will help uncover underlying oncogenic mechanisms and may offer new potential directions for the development of anticancer therapeutics and diagnostic biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.